Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-24
2007-04-24
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S478000, C548S469000
Reexamination Certificate
active
11392845
ABSTRACT:
Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione alone or in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms are also disclosed.
REFERENCES:
patent: 3031450 (1962-04-01), Fischer et al.
patent: 3322755 (1967-05-01), Roch et al.
patent: 3920636 (1975-11-01), Takahashi et al.
patent: 4001237 (1977-01-01), Partyka et al.
patent: 4001238 (1977-01-01), Partyka et al.
patent: 4047404 (1977-09-01), Hayashi
patent: 4060615 (1977-11-01), Matier et al.
patent: 4101548 (1978-07-01), Crenshaw et al.
patent: 4162316 (1979-07-01), Nishimura et al.
patent: 4209623 (1980-06-01), Juby
patent: 4880810 (1989-11-01), Lowe, III
patent: 4885301 (1989-12-01), Coates
patent: 5147875 (1992-09-01), Coates et al.
patent: 5354571 (1994-10-01), Morikawa et al.
patent: 5401774 (1995-03-01), Pamukcu et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 5488055 (1996-01-01), Kumar et al.
patent: 5608914 (1997-03-01), Keesler
patent: 5614530 (1997-03-01), Kumar et al.
patent: 5614627 (1997-03-01), Takase et al.
patent: 5658940 (1997-08-01), Muller et al.
patent: 5698579 (1997-12-01), Muller
patent: 5703098 (1997-12-01), Muller et al.
patent: 5710170 (1998-01-01), Guay et al.
patent: 5728844 (1998-03-01), Muller et al.
patent: 5728845 (1998-03-01), Muller et al.
patent: 5736570 (1998-04-01), Muller et al.
patent: 5798373 (1998-08-01), Warrellow
patent: 5801195 (1998-09-01), Muller et al.
patent: 5849770 (1998-12-01), Head et al.
patent: 5877200 (1999-03-01), Muller
patent: 5891896 (1999-04-01), Warrellow et al.
patent: 6011050 (2000-01-01), Muller et al.
patent: 6020339 (2000-02-01), Perrier et al.
patent: 6020358 (2000-02-01), Muller et al.
patent: 6034089 (2000-03-01), Han et al.
patent: 6046221 (2000-04-01), Muller et al.
patent: 6069156 (2000-05-01), Oku et al.
patent: 6162830 (2000-12-01), Connor et al.
patent: 6166041 (2000-12-01), Cavalla et al.
patent: 6177471 (2001-01-01), Menander et al.
patent: 6204275 (2001-03-01), Friesen et al.
patent: 6218400 (2001-04-01), Daugan et al.
patent: 6300335 (2001-10-01), Campbell et al.
patent: 6316472 (2001-11-01), Frenette et al.
patent: 6333354 (2001-12-01), Schudt
patent: 0 347 146 (1989-06-01), None
patent: 0 349 239 (1989-06-01), None
patent: 0 351 058 (1989-06-01), None
patent: 0 352 960 (1989-07-01), None
patent: 0 395 328 (1990-04-01), None
patent: 0 428 268 (1990-10-01), None
patent: 0 463 756 (1991-06-01), None
patent: 0 526 004 (1992-07-01), None
patent: 0 607 439 (1992-09-01), None
patent: 0 722 937 (1996-01-01), None
patent: 0 722 943 (1996-01-01), None
patent: 0 722 944 (1996-01-01), None
patent: 2 063 249 (1980-09-01), None
patent: WO 93/07149 (1993-04-01), None
patent: WO 93/12095 (1993-06-01), None
patent: WO 94/01728 (1994-01-01), None
patent: WO 94/05661 (1994-03-01), None
patent: WO 94/29277 (1994-12-01), None
patent: WO 95/19978 (1995-07-01), None
patent: WO 96/32379 (1996-10-01), None
patent: WO 97/03070 (1997-01-01), None
patent: WO 97/03675 (1997-02-01), None
patent: WO 97/03985 (1997-02-01), None
patent: WO 97/24334 (1997-07-01), None
patent: WO 98/06722 (1998-02-01), None
patent: WO 98/08848 (1998-03-01), None
patent: WO 98/14448 (1998-04-01), None
patent: WO 98/16521 (1998-04-01), None
patent: WO 98/17668 (1998-04-01), None
patent: WO 98/23597 (1998-06-01), None
patent: WO 98/38168 (1998-09-01), None
patent: WO 99/06041 (1999-02-01), None
U.S. Appl. No. 60/454,155, filed Mar. 12, 2003, G. Muller, et al.
U.S. Appl. No. 60/454,149, filed Mar. 12, 2003, G. Muller, et al.
U.S. Appl. No. 60/438,448, filed Jan. 7, 2003, G. Muller, et al.
U.S. Appl. No. 60/436,975, filed Dec. 30, 2002, G. Muller, et al.
U.S. Appl. No. 60/366,515, filed Mar. 20, 2002, G. Muller, et al.
Akazome, M. et al., 1997, “Asymmetric recognition of 1-arylethylamines by (R)-phenylglycyl-(R)-phenylglycine and its mechanism,” Tetrahedron: Asymmetry, Elsevier Scince Publishers, Amsterdam, NL, 8(14):2331-2336.
Au et al., 1998,Brit. J. Pharm. 123:1260-1266.
Baehr et al., 1979,J. Biol. Chem. 254:11669.
Baughman et al., 1990,J. Lab. Clin. Med. 115:36-42.
Beavo and Reifsnyder,Trends in Pharm., 11, 150-55, 1990.
Bissonnette et al., 1989,Inflammation13:329-339.
Bloom and Beavo 1996,Proc. Natl. Acad. Sci. USA93:14188-14192.
Brackeen, M.F. et al., 1995, “Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl) imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase”,J. Med. Chem. 38;4848-54.
Carstensen, Jens T., 1995,Drug Stability: Principles&Practice, 2nd ed., Marcel Dekker, New York, NY pp. 379-380.
Casini et al., 1964, Farmaco Ed. Sci. 19:563.
Clouse et al., 1989,J. Immunol. 142:431-438.
Derian et al., 1995, J. Immunol. 154:308-317.
Duh et al., 1989,Proc. Nat. Acad. Sci. 86:5974-5978.
Featherstone, R.L., et al., 2000, “Comparison of phosphodiesterase inhibitors of differing isoenzyme selectivity added to St. Thomas' hospital cardioplegic solution used for hypothermic preservation of rat lungs”, Am. J. Respir. Crit. Care Med. 162:850-6.
Gillespie et al., 1989,Mol. Pharm. 36:773.
Hidaka and Asano 1976,Biochem. Biophys. Acta429:485.
Hinshaw et al. 1990,Circ. Shock30:2797-292.
Holler et al., 1990,Blood75:1011-1016.
Johnson et al., 1989,Endocrinology124:1424-1427.
List et al., 1990,J. Clin. Oncol.8:1424.MDS.
Luke, G.P. et al., 1999, “Synthesis of (S)-5-(1-aminoethyl)-2-(cyclohexylmethoxy) benzamide,” Tetrahedron: Asymmetry, Elsevier Science Publishers, Amsterdam, NL, 10(22):4393-4403.
Merck Manual (1999) 17thed., 953.
Monté et al., 1990,Blood79:2670.
Muller, George, et al., 1999,Bioorganic&Medicinal Chemistry Letters9; pp. 1625-1630.
Muller et al., 1998,Bioorg.&Med Chem Lett. 8:2669-2674.
Muller, et al., 1996,J. Med. Chem. 39:3238.
Nicholson et al., 1991,Trends Pharmaco. Sci.12:19.
Shealy et al., 1965, “D- and L-thalidomide.”Chem. Indus. 12;24:1030-1.
Tierney, et al., ed., 1998, Current Medical Diagnosis & Treatment, 37thed., Appleton & Lange, pp. 499.
Verghese, et al.,Journal of Pharmacology and Experimental Therapeutics, 272(3), 1313-1320, 1995.
Van Dullemen et al., 1995,Gastroenterology, 109:129-135.
Wilen, S.H., et al., 1977,Tetrahedron33:2725.
Wilen, S.H., 1972, Tables of Resolving Agents and Optical Resoutions (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN) p. 268.
Wolff, Manfred E., ed., Burger's Medicinal Chemistry and Drug Discovery, 5th ed. 1995 172-178, 949-982.
Dredge et al., 2003, “Angiogenesis inhibitors in cancer therapy,” Curr. Opin. Investig. Drugs 4(6):667-674.
Dredge et al., 2002, “Immunological effects of thalidomide and its chemical and functional analogs,” Crit. Rev. Immunol. 22(5-6):425-437.
Dredge et al., 2002, “Recent developments in antiangiogenic therapy,” Expert Opin. Biol. Ther. 2(8):953-966.
Gee et al., 2003, “Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition,” Cancer Res. 63(23):8073-8078.
Marriott et al., 2001, “Immunotherapeutic and antitumour potential of thalidomide analogues,” Expert Opin. Biol. Ther. 1(4):1-8.
Marriott et al., 2002, “Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells,” Clin. Exp. Immunol. 130(1):75-84.
Molostvov et al., 2004, “The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures,” Br. J. Haematol. 124(3):366-375.
The Merck Manual 17th Ed. (1999), p. 448.
Shire, M.G. et al. TNF-a Inhibitors and Rheumatoid Arthritis, Exp. Opin. Ther. Patents (1998) pp. 531-544.
Gladman, D. Current Concepts In Psoriatic Arthritis, Current Opinion in Rheumatology (2002) 14: pp. 361-366.
Gladm
Muller George W.
Rohane Patricia E. W.
Schafer Peter H.
Celgene Corporation
Jones Day
Young Shawquia
LandOfFree
Methods of the treatment of psoriatic arthritis using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of the treatment of psoriatic arthritis using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of the treatment of psoriatic arthritis using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3762782